Almirall, LLC

Almirall and Absci have expanded their AI drug discovery collaboration to include a second dermatology target following successful delivery of AI-designed antibody leads against a difficult-to-drug target.

AMD has invested $20 million in Absci and formed a partnership to power AI-driven drug discovery platforms, marking the chipmaker's strategic entry into pharmaceutical research and development.

Phase 3 trial data demonstrates lebrikizumab's efficacy in managing atopic dermatitis (AD) symptoms over 52 weeks, a significant improvement over the 16-week maintenance shown in previous trials.

• Eli Lilly's EBGLYSS demonstrated significant improvements in skin condition and itch relief in moderate-to-severe atopic dermatitis patients who had an inadequate response to dupilumab. • In the Phase IIIb ADapt study, 57% of patients achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) score by week 16, increasing to 60% by week 24. • More than half of the patients experienced significant itch relief, with 53% at week 16 and 62% at week 24 showing at least a four-point improvement from baseline. • Clear or almost clear facial dermatitis was observed in 52% of patients treated with EBGLYSS by week 24, with a safety profile consistent with prior Phase III trials.

Tirbanibulin 1% ointment demonstrates efficacy and tolerability in treating actinic keratosis (AK) across larger skin fields (100 cm²) on the face and scalp.

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for treating moderate-to-severe atopic dermatitis in adults and adolescents (12+ years, >=40kg).

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for treating moderate-to-severe atopic dermatitis (eczema) in patients 12 years and older.

The FDA has approved Eli Lilly's EBGLYSS (lebrikizumab-lbkz) for treating moderate-to-severe atopic dermatitis in patients aged 12 and older, offering a new targeted treatment option.

Almirall has launched the POSITIVE study, the first dermatological research to assess patient wellbeing as a primary endpoint using the WHO-5 questionnaire in 780 adults with moderate-to-severe psoriasis.